FOFrances P. O'MAlley

Frances P. O'MAlley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years

Research Subjects


Frances P. O'MAlley has a total of 108 co-authors. Here are the top co-authors by number of shared publications:

  • Irene Andrulis

    From the Department of Pathology and Laboratory Medicine, Mount Sinai Hospital and University of Toronto, Toronto, Ontario (Dr O'Malley and Ms Have); the Departments of Pathology (Dr Thomson) and Medical Oncology (Dr Gelmon), British Columbia Cancer Agency, Vancouver; the Department of Clinical Epidemiology and Biostatistics (Mr Julian), the Program in Evidence Based Care (Ms Cosby), and the Department of Medicine, Division of Radiation Oncology (Dr Whelan), McMaster University, Hamilton...

    3 shared publications
  • Irene L. Andrulis

    Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada

    3 shared publications
  • Marguerite Ennis

    From the Department of Laboratory Medicine and Pathobiology, University of Toronto (Drs Grin and O'Malley) and the Department of Pathology, Mount Sinai Hospital (Drs Grin and O'Malley), Toronto, Ontario; and the Department of Pathology, University of Calgary, Alberta (Dr Horne). Dr Ennis is an applied statistician in private practice in Markham, Ontario, Canada

    3 shared publications
  • Shikha Bose

    3 shared publications
  • Andrea Grin

    From the Department of Laboratory Medicine and Pathobiology, University of Toronto (Drs Grin and O'Malley) and the Department of Pathology, Mount Sinai Hospital (Drs Grin and O'Malley), Toronto, Ontario; and the Department of Pathology, University of Calgary, Alberta (Dr Horne). Dr Ennis is an applied statistician in private practice in Markham, Ontario, Canada

    2 shared publications
  • Anna Marie Mulligan

    Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada

    2 shared publications

Latest Publications

  • Open Access

    Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry

    by Letitia D Smith, Andrea A Tesoriero, Ee M Wong, Susan J Ramus, Frances P O'MAlley, Anna Marie Mulligan, Mary Beth Terry, Ruby T Senie, Regina M Santella, Esther M John, et al.

    Introduction: Selecting women affected with breast cancer who are most likely to carry a germline mutation in BRCA1 and applying the most appropriate test methodology remains challenging for cancer genetics services. We sought to test the value of selecting women for BRCA1 mutation testing on the basis of family history and/or breast tumour morphology criteria as well as the value of testing for large genomic alterations in BRCA1 . Methods: We studied women participating in the Breast Cancer Family Registry (BCFR), recruited via population-based sampling, who had been diagnosed with breast cancer before the age of 40 years who had a strong family history of breast or ovarian cancer (n = 187) and/or a first primary breast tumour with morphological features consistent with carrying a BRCA1 germline mutation (n = 133; 37 met both criteria). An additional 184 women diagnosed before the age of 40 years who had a strong family history of breast or ovarian cancer and who were not known to carry a germline BRCA1 mutation were selected from among women who had been recruited into the BCFR from clinical genetics services. These 467 women had been screened for BRCA1 germline mutations, and we expanded this testing to include a screen for large genomic BRCA1 alterations using Multiplex Ligation-dependent Probe Amplification. Results: Twelve large genomic BRCA1 alterations were identified, including 10 (4%) of the 283 women selected from among the population-based sample. In total, 18 (12%), 18 (19%) and 16 (43%) BRCA1 mutations were identified in the population-based groups selected on the basis of family history only (n = 150), the group selected on the basis of tumour morphology only (n = 96) and meeting both criteria (n = 37), respectively. Conclusions: Large genomic alterations accounted for 19% of all BRCA1 mutations identified. This study emphasises the value of combining information about family history, age at diagnosis and tumour morphology when selecting women for germline BRCA1 mutation testing as well as including a screen for large genomic alterations.


  • Protocol for the examination of specimens from patients with invasive carcinoma of the breast.

    by Susan C Lester, Shikha Bose, Yunn-Yi Chen, James L Connolly, Monica E De Baca, Patrick L Fitzgibbons, Daniel F Hayes, Celina Kleer, Frances P O'Malley, David L Page, et al.


    • 1 May 2009
      • Vol. 29  (5) , 1557-62

    Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.

    by Reuben J Broom, Patricia A Tang, Christine Simmons, Louise Bordeleau, Anna Marie Mulligan, Frances P O'Malley, Naomi Miller, Irene L Andrulis, Darren M Brenner, Mark J Clemons

    Changes in the receptor profile between primary and metastatic breast cancer tissue have been suggested. The degree of hormone receptor discordance in archival paired pathological samples was evaluated. Archival data were collected on 100 patients for whom tissue from primary and metastatic sites was available. Estrogen receptor (ER), progesterone receptor (PR) and Her-2/neu status in the primary and metastasis were compared. The discordance rate for ER was 17.7% (2-sided p=0.0039) with 9.7% of tumours changing from ER-positive to ER-negative and 8.0% changing from ER-negative to ER-positive. The discordance rate for PR was 37.3% (2-sided p<0.0001), with all of these tumours changing from PR-positive to PR-negative. No significant discordance for Her-2/neu was found. This series suggests that significant discordance exists for hormone receptor status between primary and metastatic breast cancer samples. Loss of PR was particularly frequent.


  • Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast.

    by Susan C Lester, Shikha Bose, Yunn-Yi Chen, James L Connolly, Monica E De Baca, Patrick L Fitzgibbons, Daniel F Hayes, Celina Kleer, Frances P O'Malley, David L Page, et al.


  • Measuring extent of ductal carcinoma in situ in breast excision specimens: a comparison of 4 methods.

    by Andrea Grin, Garnet Horne, Marguerite Ennis, Frances P O'Malley

    Measuring the extent of nonpalpable ductal carcinoma in situ (DCIS) in a breast specimen is challenging but important because it influences patient management. There is no standardized method for estimating the extent of DCIS, although serial sequential sampling with mammographic correlation is considered an accurate method. To estimate the extent of DCIS using various methods and to compare these estimations with the extent as determined by the serial sequential sampling method. A total of 78 primary breast excisions with DCIS were retrospectively reviewed. All specimens had been sampled using the serial sequential sampling method, which involved mapping the location of each block on the sliced specimen radiograph and calculating the extent through 3-dimensional reconstruction. The other measures for estimating extent included (1) calculating size based on areas of calcification, (2) recording the number of blocks involved by DCIS and multiplying that number by 0.3 cm, and (3) measuring the largest extent of DCIS on a single slide. All 3 alternative methods tended to underestimate the DCIS. Discrepancies became more pronounced as size increased. The percentage of cases estimated to within 1 cm of the serial sequential sampling method were 81%, 72%, and 50%, respectively, for the calcification, blocks, and single-slide methods; differences of more than 2 cm were seen in 9%, 8%, and 30% of cases, respectively. The single-slide method performed poorly and should be used only when DCIS is limited to a single slide. Although the calcification and the blocks methods gave better estimates, both produced substantial underestimates and/or overestimates that could affect clinical decision making.


  • Open Access

    Measuring Extent of Ductal Carcinoma In Situ in Breast Excision Specimens: A Comparison of 4 Methods

    by Andrea Grin, Garnet Horne, Marguerite Ennis, Frances P. O'MAlley

    Context. —Measuring the extent of nonpalpable ductal carcinoma in situ (DCIS) in a breast specimen is challenging but important because it influences patient management. There is no standardized method for estimating the extent of DCIS, although serial sequential sampling with mammographic correlation is considered an accurate method. Objective. —To estimate the extent of DCIS using various methods and to compare these estimations with the extent as determined by the serial sequential sampling method. Design. —A total of 78 primary breast excisions with DCIS were retrospectively reviewed. All specimens had been sampled using the serial sequential sampling method, which involved mapping the location of each block on the sliced specimen radiograph and calculating the extent through 3-dimensional reconstruction. The other measures for estimating extent included (1) calculating size based on areas of calcification, (2) recording the number of blocks involved by DCIS and multiplying that number by 0.3 cm, and (3) measuring the largest extent of DCIS on a single slide. Results. —All 3 alternative methods tended to underestimate the DCIS. Discrepancies became more pronounced as size increased. The percentage of cases estimated to within 1 cm of the serial sequential sampling method were 81%, 72%, and 50%, respectively, for the calcification, blocks, and single-slide methods; differences of more than 2 cm were seen in 9%, 8%, and 30% of cases, respectively. Conclusions. —The single-slide method performed poorly and should be used only when DCIS is limited to a single slide. Although the calcification and the blocks methods gave better estimates, both produced substantial underestimates and/or overestimates that could affect clinical decision making.


  • HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab.

    by Frances P O'Malley, Tom Thomson, Jim Julian, Cherry Have, Roxanne Cosby, Roxanne Crosby, Karen Gelmon, Irene Andrulis, Tim Whelan

    The development of trastuzumab has led to new therapeutic strategies for patients with breast cancer. Trastuzumab has been shown to only be effective in those patients whose cancers are HER2 positive by either immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH). To determine the accuracy of HER2 testing in 2 provinces in Canada. Patients with metastatic breast cancer diagnosed between 1999 and 2002 who were HER2 positive in the local laboratories were included in this study. All cases were retested centrally, by IHC (using 4 methods) and FISH. In addition, 205 locally reported HER2-negative metastatic breast cancer cases were retested centrally. Concordance between the 505 local IHC-positive cases with central IHC testing varied between 79.3% and 89.6% depending on the IHC method and scoring method used. HER2 gene amplification by FISH was present in 86.1% of local IHC-positive cases. Concordance between the 205 local IHC-negative tumors with central testing ranged between 94.8% and 100% for IHC and was 98.5% for FISH. This study demonstrated that locally reported HER2-negative results were highly accurate, but less accuracy was demonstrated with local HER2-positive results. These results emphasize the need for participation in a quality assurance program.


  • Open Access

    HER2 Testing in a Population-Based Study of Patients With Metastatic Breast Cancer Treated With Trastuzumab

    by Frances P. O'MAlley, Tom Thomson, Jim Julian, Cherry Have, Roxanne Cosby, Karen Gelmon, Irene Andrulis, Tim Whelan

    Context. —The development of trastuzumab has led to new therapeutic strategies for patients with breast cancer. Trastuzumab has been shown to only be effective in those patients whose cancers are HER2 positive by either immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH). Objective. —To determine the accuracy of HER2 testing in 2 provinces in Canada. Design. —Patients with metastatic breast cancer diagnosed between 1999 and 2002 who were HER2 positive in the local laboratories were included in this study. All cases were retested centrally, by IHC (using 4 methods) and FISH. In addition, 205 locally reported HER2-negative metastatic breast cancer cases were retested centrally. Results. —Concordance between the 505 local IHC-positive cases with central IHC testing varied between 79.3% and 89.6% depending on the IHC method and scoring method used. HER2 gene amplification by FISH was present in 86.1% of local IHC-positive cases. Concordance between the 205 local IHC-negative tumors with central testing ranged between 94.8% and 100% for IHC and was 98.5% for FISH. Conclusions. —This study demonstrated that locally reported HER2-negative results were highly accurate, but less accuracy was demonstrated with local HER2-positive results. These results emphasize the need for participation in a quality assurance program.


  • An update on apocrine lesions of the breast

    by F P O’mAlley, A Bane

    Apocrine change occurs in a spectrum of benign lesions in the female breast and is also demonstrated in a subgroup of in situ and invasive carcinomas. Recent research has focused on the molecular phenotype of both benign and malignant apocrine lesions. This review will briefly summarize the morphological characteristics and risk associations of the spectrum of apocrine proliferations, but will focus on the updated molecular studies of both in situ and invasive apocrine carcinomas.